Semaglutide (Novo Nordisk, Denmark) is a glucagon-like peptide-1 (GLP-1) analog for the treatment of type 2 diabetes (T2D) [1, 2]. The gene discussed is GLP1R; the disease is type 2 diabetes mellitus.